BR112015025699A2 - modulação de especificidade de polipeptídeo estruturado - Google Patents

modulação de especificidade de polipeptídeo estruturado

Info

Publication number
BR112015025699A2
BR112015025699A2 BR112015025699A BR112015025699A BR112015025699A2 BR 112015025699 A2 BR112015025699 A2 BR 112015025699A2 BR 112015025699 A BR112015025699 A BR 112015025699A BR 112015025699 A BR112015025699 A BR 112015025699A BR 112015025699 A2 BR112015025699 A2 BR 112015025699A2
Authority
BR
Brazil
Prior art keywords
modulation
polypeptide specificity
structured polypeptide
structured
specificity
Prior art date
Application number
BR112015025699A
Other languages
English (en)
Other versions
BR112015025699B1 (pt
Inventor
Stace Catherine
Paul Teufel Daniel
Walker Edward
Tite John
Original Assignee
Bicycle Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycle Therapeutics Ltd filed Critical Bicycle Therapeutics Ltd
Publication of BR112015025699A2 publication Critical patent/BR112015025699A2/pt
Publication of BR112015025699B1 publication Critical patent/BR112015025699B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)

Abstract

resumo patente de invenção: "modulação de especificidade de polipeptídeo estruturado". a invenção descreve ligantes de peptídeo específicos para calicreína de plasma humano.
BR112015025699-6A 2013-04-11 2014-04-11 Ligante de peptídeo específico para calicreína humana e composição compreendendo o mesmo BR112015025699B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1306623.8 2013-04-11
GB201306623A GB201306623D0 (en) 2013-04-11 2013-04-11 Modulation of structured polypeptide specificity
PCT/EP2014/057440 WO2014167122A1 (en) 2013-04-11 2014-04-11 Modulation of structured polypeptide specificity

Publications (2)

Publication Number Publication Date
BR112015025699A2 true BR112015025699A2 (pt) 2017-10-10
BR112015025699B1 BR112015025699B1 (pt) 2023-07-18

Family

ID=

Also Published As

Publication number Publication date
EP2983722B1 (en) 2018-12-12
SG10201805806RA (en) 2018-08-30
PL2983722T3 (pl) 2019-08-30
CN105307686B (zh) 2019-05-28
TR201903649T4 (tr) 2019-04-22
JP2016519683A (ja) 2016-07-07
CA2908406C (en) 2021-07-20
JP6785932B2 (ja) 2020-11-18
DK2983722T3 (en) 2019-04-01
US20180362585A1 (en) 2018-12-20
AU2014253036A1 (en) 2015-10-22
PT2983722T (pt) 2019-03-25
WO2014167122A1 (en) 2014-10-16
US20210079043A1 (en) 2021-03-18
SG11201508017QA (en) 2015-10-29
CA2908406A1 (en) 2014-10-16
HK1221172A1 (zh) 2017-05-26
AU2014253036B2 (en) 2019-01-31
US20160046673A1 (en) 2016-02-18
US10870679B2 (en) 2020-12-22
NZ713439A (en) 2021-06-25
US11753444B2 (en) 2023-09-12
JP6588890B2 (ja) 2019-10-09
JP2020019778A (ja) 2020-02-06
GB201306623D0 (en) 2013-05-29
EP2983722A1 (en) 2016-02-17
ES2715406T3 (es) 2019-06-04
CN105307686A (zh) 2016-02-03
RU2674070C2 (ru) 2018-12-04
US10118947B2 (en) 2018-11-06
RU2015147869A (ru) 2017-05-16

Similar Documents

Publication Publication Date Title
CY1123865T1 (el) Τροποποιηση της εξειδικευσης δομημενου πολυπεπτιδιου
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
SG10201805806RA (en) Modulation of Structured Polypeptide Specificity
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
MX2020008436A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
EA201690314A1 (ru) Анти-garp-белок и его применения
BR112015023457A2 (pt) sistemas adesivos cationicamente curáveis/ de cianoacrilato de duas partes
UY34885A (es) Proteínas de unión anti-mesotelina
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
BR112019007613A2 (pt) terapia de combinação para inibição de c3
IN2014DN05885A (pt)
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
EA201891299A1 (ru) Терапевтические антитела к cd9
IN2013MU00848A (pt)
BR112018003493A2 (pt) variantes de quimosina com propriedades aperfeiçoadas
CY1125143T1 (el) Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
ZA201803551B (en) Personal care composition comprising taurine, arginine, glycine
PH12015501854A1 (en) Factor ix polypeptide formulations
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
BR112015005738A2 (pt) formulações orais de angiotensina
BR112016007816A2 (pt) composições peptídicas inovadoras
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01), C07K 14/435 (2006.01)

B25D Requested change of name of applicant approved

Owner name: BICYCLERD LIMITED. (GB)

B25G Requested change of headquarter approved

Owner name: BICYCLERD LIMITED. (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023005162-9 PROTOCOLO 870230023577 EM 20/03/2023 18:24.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/04/2014, OBSERVADAS AS CONDICOES LEGAIS